title: CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
abstract: CD163+ tumor-associated macrophages (TAMs) play an important role in the progression of cancer. However, the significance of CD163+ TAMs in malignant pleural effusion (MPE) is still unclear. The aim of this study is to evaluate the prognostic value of CD163+ TAMs in MPE, and the regulatory effect of an immune adjuvant (pseudomonas aeruginosa - mannose-sensitive hemagglutinin, PA-MSHA, which is used for MPE treatment in clinic) on CD163+ TAMs in MPE. Here, we found that the percentage of CD163+ TAMs in MPE was significantly higher than that in non-malignant pleural effusion (P<0.001). More importantly, CD163+ TAMs in MPE patients were an independent prognostic factor for progression-free survival. M2-related cytokines were highly expressed in MPE-derived CD163+ TAMs than in MPE-derived CD163- macrophages (P<0.05). CD163+ TAMs frequency in MPE patients was obviously reduced after PA-MSHA treatment in clinic (P<0.05). After treatment with PA-MSHA, M2 macrophages were re-educated to M1 macrophages in vitro. TLR4 blocking antibody inhibited M2 macrophages polarization to M1 macrophages induced by PA-MSHA. These findings highlight that accumulation of CD163+ TAMs in MPE caused by lung cancer is closely correlated with poor prognosis. CD163+ TAMs are associated with therapeutic effect in MPE. PA-MSHA re-educates CD163+ TAMs to M1 macrophages through TLR4-mediated pathway in MPE.
authors: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Li
authors: L
authors: Yang
authors: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.|School of Life Sciences, Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Fei
authors: F
authors: Wang
authors: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Liping
authors: L
authors: Wang
authors: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Lan
authors: L
authors: Huang
authors: Department of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Jing
authors: J
authors: Wang
authors: Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago IL, USA.
authors: Bin
authors: B
authors: Zhang
authors: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.|School of Life Sciences, Zhengzhou University, Zhengzhou, Henan Province, China.|Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
authors: Yi
authors: Y
authors: Zhang
mesh_terms: D015703:Antigens, CD / Q000097:blood* / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood / Q000276:immunology; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D008264:Macrophages / Q000276:immunology / Q000378:metabolism*; D016066:Pleural Effusion, Malignant / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000097:blood* / Q000276:immunology; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D000098902:CD163 Antigen; D011956:Receptors, Cell Surface
keywords: CD163; malignant pleural effusion; prognostic biomarker; therapeutic effect; tumor-associated macrophages